Rieken, Stefan

[["dc.bibliographiccitation.firstpage","383"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Harrabi, Semi"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Freudlsperger, Christian"],["dc.contributor.author","Kargus, Steffen"],["dc.contributor.author","Plinkert, Peter"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Adeberg, Sebastian"],["dc.date.accessioned","2020-07-16T10:33:52Z"],["dc.date.available","2020-07-16T10:33:52Z"],["dc.date.issued","2019-03-19"],["dc.description.abstract","Purpose: The aim of the current evaluation was to assess central nervous system necrosis (CNSN) after re-irradiation with carbon ions (CR) in two-hundred seventeen (n = 217) patients with recurrent head-and-neck cancer (HNC). Methods: Thirty-six (n = 36) patients with CNSN were assessed retrospectively regarding clinical symptoms and radiographic response. Results: CNSN were classified according to clinical management in line with the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. At a median follow-up of 25.3 months (range 3.3⁻79.9 months), the median time interval until occurrence of grade I, II, and III CNSN was 9.2 months (range 2.8⁻75.0 months), 10.2 months (range 2.3⁻60.5 months), and 16.6 months (range 8.7⁻32.5 months), respectively. In one patient with an adenocarcinoma infiltrating the frontal lobe, an extensive CNSN grade IV was suspected but the patient declined surgical intervention. Radiographic response after treatment of CNSN grade I, II, and III, defined as ≥25% reduction of the T2 alteration on Magnetic Resonance Imaging (MRI), was observed in 4 (16.0%), 5 (29.4%), and 4 (80%) patients, respectively. Conclusion: CNSN occurred late and frequent after re-irradiation with carbon ions in patients with HNC infiltrating the base of skull. The clinical outcome with adequate treatment was encouraging but correct diagnosis of CNSN remains challenging."],["dc.identifier.doi","10.3390/cancers11030383"],["dc.identifier.pmid","30893824"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67183"],["dc.language.iso","en"],["dc.relation.issn","2072-6694"],["dc.title","Clinical Management of Blood⁻Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Kappes, Jutta"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Herth, Felix"],["dc.contributor.author","Heußel, Claus"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Steins, Martin"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-10T07:20:41Z"],["dc.date.available","2020-07-10T07:20:41Z"],["dc.date.issued","2017"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66973"],["dc.title","P17-2-jD Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy"],["dc.type","report"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2208"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Head & Neck"],["dc.bibliographiccitation.lastpage","2214"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Bulut, Olcay Cem"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Plinkert, Peter"],["dc.contributor.author","Jensen, Alexandra"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Adeberg, Sebastian"],["dc.date.accessioned","2020-07-10T08:19:46Z"],["dc.date.available","2020-07-10T08:19:46Z"],["dc.date.issued","2019"],["dc.description.abstract","To evaluate clinical outcome and functional larynx preservation after radiotherapy (RT) for adenoid cystic carcinoma (ACC) of the larynx."],["dc.identifier.doi","10.1002/hed.25678"],["dc.identifier.pmid","30723979"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66978"],["dc.language.iso","en"],["dc.relation.eissn","1097-0347"],["dc.relation.issn","1043-3074"],["dc.title","The role of organ- and function-preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1420"],["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Windisch, Paul"],["dc.contributor.author","Ehret, Felix"],["dc.contributor.author","Baur, Melissa"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Haefner, Matthias F"],["dc.contributor.author","Krauss, Juergen"],["dc.contributor.author","Kargus, Steffen"],["dc.contributor.author","Freudlsperger, Christian"],["dc.contributor.author","Plinkert, Peter"],["dc.contributor.author","Flechtenmacher, Christa"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T10:33:12Z"],["dc.date.available","2020-07-16T10:33:12Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: To assess outcomes and treatment related toxicity following intensity-modulated radiotherapy (IMRT) and a Carbon Ion Radiotherapy (CIRT) boost for salivary duct carcinoma (SDC). Methods: Twenty-eight consecutive patients with SDC who underwent a postoperative (82%) or definitive (18%) radiation therapy between 2010 and 2017 were assessed in this retrospective single-center analysis. CIRT boost was delivered with median 18 Gy(RBE) in 6 daily fractions, followed by an TomoTherapy®-based IMRT (median 54 Gy in 27 daily fractions). Treatment-related acute toxicity was assessed according to CTCAE Version 4. Results: Tumors were most commonly located in the major salivary glands (n = 25; 89%); 23 patients (82%) received previous surgery (R0: 30%; R1: 57%; R2: 4%; RX: 19%). Median follow-up was 30 months. Four patients (14%) experienced a local relapse and 3 (11%) developed locoregional recurrence. The two-year local control (LC) and locoregional control (LRC) was 96 and 93%, respectively. Median disease-free survival (DFS) was 27 months, metastasis-free survival (MFS) was 69 months, and overall survival (OS) was 93 months. Acute grade 3 toxicity occurred in 11 patients (mucositis, dermatitis, xerostomia; n = 2 each (7%) were the most common) and 2 osteonecroses of the mandibular (grade 3) occurred. No patients experienced grade ≥4 toxicities. Conclusions: Multimodal therapy approaches with surgery followed by IMRT and CIRT boost for SDC leads to good local and locoregional disease control. However, the frequent occurrence of distant metastases limits the prognosis and requires optimization of adjuvant systemic therapies."],["dc.identifier.doi","10.3389/fonc.2019.01420"],["dc.identifier.pmid","31921675"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67174"],["dc.language.iso","en"],["dc.relation.issn","2234-943X"],["dc.title","Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S1045"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.lastpage","S1046"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Hoerner-Rieber, Juliane"],["dc.contributor.author","Kappes, Jutta"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Bischoff, Helge"],["dc.contributor.author","Herth, Felix Jf"],["dc.contributor.author","Heussel, Claus"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Steins, Martin"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-10T08:22:55Z"],["dc.date.available","2020-07-10T08:22:55Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1016/j.jtho.2016.11.1460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67016"],["dc.relation.issn","1556-0864"],["dc.title","P2.05-025 9-Year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2059"],["dc.bibliographiccitation.issue","15, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","2059"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Combs, Stephanie E"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Herfarth, Klaus K"],["dc.contributor.author","Unterberg, Andreas"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T10:31:30Z"],["dc.date.available","2020-07-16T10:31:30Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.2059"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67151"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Opfermann, Nils"],["dc.contributor.author","Hoerner-Rieber, Juliane"],["dc.contributor.author","Repka, Michael"],["dc.contributor.author","Kappes, Jutta"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Bischoff, Helge"],["dc.contributor.author","Herth, Felix"],["dc.contributor.author","Heußel, Claus"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Steins, Martin"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-10T07:20:36Z"],["dc.date.available","2020-07-10T07:20:36Z"],["dc.date.issued","2016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66972"],["dc.title","9-year experience: Prophylactic cranial irradiation in extensive disease small-cell lung cancer"],["dc.type","report"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","115"],["dc.bibliographiccitation.journal","Oral Oncology"],["dc.bibliographiccitation.lastpage","123"],["dc.bibliographiccitation.volume","97"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Heusel, Astrid"],["dc.contributor.author","Mock, Andreas"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Hoerner-Rieber, Juliane"],["dc.contributor.author","Forster, Tobias"],["dc.contributor.author","Katayama, Sonja"],["dc.contributor.author","Kargus, Steffen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Plinkert, Peter"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Adeberg, Sebastian"],["dc.date.accessioned","2020-07-10T08:23:18Z"],["dc.date.available","2020-07-10T08:23:18Z"],["dc.date.issued","2019"],["dc.description.abstract","Data regarding treatment and survival outcome of patients with mucoepidermoid carcinoma of the head and neck are limited to case reports and case series. As a consequence of lacking evidence, treatment guidelines do not exist. We aimed to analyze the effect of modern radiotherapy in form of intensity modulated radiotherapy (IMRT) either with simultaneously integrated boost or carbon ion boost on local control and survival for a relatively large patient collective."],["dc.identifier.doi","10.1016/j.oraloncology.2019.08.018"],["dc.identifier.pmid","31494395"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67021"],["dc.language.iso","en"],["dc.relation.eissn","1879-0593"],["dc.relation.issn","1368-8375"],["dc.title","The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","641"],["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Böhm, Karina"],["dc.contributor.author","Weber, Dorothea"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Schlaich, Fabian"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Paul, Angela"],["dc.contributor.author","Haefner, Matthias F."],["dc.contributor.author","Katayama, Sonja"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Hoegen, Philipp"],["dc.contributor.author","Löw, Sarah"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Bernhardt, Denise"],["dc.date.accessioned","2020-07-16T10:33:04Z"],["dc.date.available","2020-07-16T10:33:04Z"],["dc.date.issued","2018"],["dc.description.abstract","Introduction: The purpose of this article is to report our institution's 10-year experience on palliative radiotherapy for the treatment of leptomeningeal carcinomatosis (LC), assessing survival, neurologic outcome, and prognostic factors. Patients and methods: We retrospectively analyzed 110 patients who received palliative radiotherapy for LC between 2008 and 2018. The most common histologies were breast cancer (n = 43, 39.1%) and non-small cell lung cancer (NSCLC) (n = 31, 28.2%). Radiotherapy was administered as whole-brain radiotherapy (WBRT) (n = 51, 46.4%), focal spinal RT (n = 11, 10.0%) or both (n = 47, 42.7%). Twenty-five patients (22.7%) were selected for craniospinal irradiation. Clinical performance and neurologic function were quantified on the neurologic function scale (NFS) before and in response to therapy. A Cox Proportional Hazards model with univariate and multivariate analysis was fitted for survival. Results: Ninety-eight patients (89.1%) died and 12 (10.9%) were alive at the time of analysis. Median OS from LC diagnosis and from the beginning of RT was 13.9 weeks (IQR: 7.1-34.0) and 9.9 weeks (IQR: 5.3-26.3), respectively. In univariate analysis, prognostic of longer OS were a Karnofsky performance scale index (KPI) of ≥70% (HR 0.20, 95%-CI: [0.13; 0.32], p < 0.001), initially moderate neurological deficits (NFS ≤2) (HR 0.32, 95% CI: [0.19; 0.52], p < 0.001), symptom response to RT (HR 0.41, 95%-CI: [0.26; 0.67], p < 0.001) and the administration of systemic therapy (HR 0.51, 95%-CI: [0.33; 0.78], p = 0.002). Prognostic of inferior OS were high-grade myelosuppression (HR 1.78, 95% CI: [1.06; 3.00], p = 0.03) and serum LDH levels >500 U/l (HR 3.62, 95% CI: [1.76; 7.44], p < 0.001). Clinical performance, symptom response and serum LDH stayed independently prognostic for survival in multivariate analysis. RT was well-tolerated and except for grade III myelosuppression in 19 cases (17.3%), no high-grade acute toxicities were observed. Neurologic symptom stabilization was achieved in 83 cases (75.5%) and a sizeable improvement in 39 cases (35.5%). Conclusion: Radiotherapy is a well-tolerated and efficacious means of providing symptom palliation for patients with LC, delaying neurologic deterioration while probably not directly influencing survival. Prognostic factors such as clinical performance, neurologic response and serum LDH can be used for patient stratification to facilitate treatment decisions."],["dc.identifier.doi","10.3389/fonc.2018.00641"],["dc.identifier.pmid","30671384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67172"],["dc.language.iso","en"],["dc.relation.issn","2234-943X"],["dc.title","Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","203"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiation oncology"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Harrabi, Semi B"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Welzel, Thomas"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Habermehl, Daniel"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Combs, Stephanie E"],["dc.date.accessioned","2020-07-16T10:29:42Z"],["dc.date.available","2020-07-16T10:29:42Z"],["dc.date.issued","2014-09-16"],["dc.description.abstract","There are already numerous reports about high local control rates in patients with craniopharyngioma but there are only few studies with follow up times of more than 10 years. This study is an analysis of long term control, tumor response and side effects after fractionated stereotactic radiotherapy (FSRT) for patients with craniopharyngioma."],["dc.identifier.doi","10.1186/1748-717X-9-203"],["dc.identifier.pmid","25227427"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67128"],["dc.language.iso","en"],["dc.relation.issn","1748-717X"],["dc.title","Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]